Join us for our Q2 2025 Earnings & Webcast today @ 8:30am EST as we review key updates and strategic progress. 🔗Listen live: 🔗 Read the release here: #inkt #Biotech #Earnings #Q22025

New peer-reviewed case study in Oncogene describes our allogeneic iNKT cell therapy, agenT-797, clinical response in metastatic, treatment-refractory testicular cancer. Promising immune activity seen in combo with anti–PD-1 therapy. Read here:

MiNK has been awarded a NIAID grant to advance its allo-iNKT cell therapy for patients undergoing stem cell transplant. This non-dilutive funding supports collaborative research with the University of Wisconsin. Learn more: #CellTherapy #NIH #INKT

Yesterday at #AACRIO25, we presented new translational insights highlighting the powerful synergy between MiNK’s allo-iNKT cells, checkpoint inhibitors, and chemotherapy in #GastricCancer. Read more about the data:

MiNK is live in Los Angeles for #AACRIO25. Tune in later today to hear new translational data from the ongoing Ph2 study evaluating allo-iNKTs (agenT-797) in combination with @Agenus_Bio's BOT/BAL & chemotherapy in refractory #GastricCancer. Learn more:

We are excited to announce a new collaboration with Autonomous Therapeutics. By combining our iNKT cell platform with their encrypted RNA technology, we aim to develop innovative and potentially transformative therapies for metastatic cancers. Learn more:

RT @CathyEngMD: Bot/Bal #immunotherapy in #coloncancer #NEST 1/2 @Agenus_Bio with very promising data in early MSI-s/MSI-H #coloncancer ! @….

Yesterday Dr. Terese Hammond presented data at the American Thoracic Society #ATS2024 Annual Meeting in San Diego, CA, showcasing the clinical activity of MiNK’s allogeneic iNKT cells in respiratory distress. Learn more:

This quarter we made significant strides across our iNKT cell programs, including generating clinical data from our agenT-797 program, strengthening our financial position, and advancing our innovative next-generation therapies. Read more in our Q1 report:

Today we’ve announced a $5.8M in private placement financing to accelerate MiNK-215's clinical development and the appointment of a Board Observer. Learn more:

#ICYMI - check out our presentation from #AACR2024 yesterday: Thank you to everyone who stopped by our poster session to hear new preclinical data on MiNK-215’s activity against colorectal cancer liver metastases. #CellTherapy #CancerResearch #INKT

Today we announced fourth quarter and year-end of 2023 results. Our year was marked by progress across our clinical programs, manufacturing, and research team, which continue to solidify our leadership in the field of #iNKT cell therapy. Read more:

Today we recognize and thank all the women who inspire, lead, and break barriers. MiNK is proud to #InspireInclusion with our dedicated team of female leaders who help pioneer our commitment to delivering #iNKT cell therapies for patients. #InternationalWomensDay #IWD2024

Stay tuned for MiNK’s upcoming presentation at #AACR24. On April 8, MiNK will present preclinical data on MiNK-215, our IL-15 armored FAP-targeting CAR-iNKT cell therapy, demonstrating its unique potential against liver metastases in MSS CRC. Learn more:

Today MiNK Chief Scientific Officer, Marc van Dijk, joins the @CAR_TCell Summit Europe, where he will discuss our clinical experience with allogeneic iNKTs and the exciting future for this novel cell therapy approach. Learn more: . #iNKT #CellTherapy

We are proud to partner with @YJanjigianMD on a phase 2 study in 2L gastroesophageal cancers. The first patient has been dosed, and the trial will investigate our allo-iNKT cell therapy, agenT-797, in combination with @Agenus_Bio's BOT/BAL, and chemo.

Today @naturecomms published results from our trial of allogeneic iNKT cells in ARDS, highlighting the unique attributes of iNKTs and their potential in mitigating respiratory illnesses. We thank all the patients who participated in this study. Learn more:

New publication from @oncogenejournal spotlights a compelling case study of a durable response to our investigational #iNKT cell therapy, agenT-797 in PD-1 refractory gastric cancer. Read more about the potential of iNKT cells to combat resistance to ICIs:

MiNK and @ImmunoScape collaborate to develop next-generation TCRs for solid tumors. The partnership aims to accelerate the development of TCR-based therapies against novel targets in T cells, #iNKT cells, and other modalities. Learn more:

MiNK announced its third quarter 2023 financial results and provided a corporate update, highlighting advancements across its iNKT cell therapy platform. Read more about these results: #iNKT #CellTherapy